https://www.selleckchem.com/products/nt157.html
Concerns have been raised about the limited health system capacity for identification of patients who are eligible for a disease-modifying Alzheimer's treatment (DMT). Blood-based biomarker (BBBM) tests are a promising tool to improve triaging at the primary care level. We projected their impact on cost of and wait times during the diagnostic process. We compare four scenarios for triaging patients at the primary care level from the perspective of the U.S. health care system (1) cognitive test only (Mini Mental State Examination [MMSE]),
Like
Comment
Share
